Focal Prostate Cancer Therapy Splits Doctors on Long-Term Data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Focal therapy uses FDA-authorized technologies — cryotherapy, laser ablation, and high-intensity focused ultrasound (HIFU) — to destroy MRI-identified prostate lesions, offering a less aggressive alternative to removing or irradiating the entire gland.
- A U.K. study found that 10 years after focal therapy, only 0.1% of patients died of prostate cancer — survival outcomes comparable to radical surgery or radiation, with higher satisfaction and lower rates of incontinence and erectile dysfunction.
- The American Urological Association still classifies focal therapy as experimental, recommending it only as part of studies and prospective registries; just 1.3% of U.S. prostate cancer patients received it.
- A recent paper found that half of focal therapy patients had cancers outside the AUA's recommended risk range — either higher-risk disease or low-grade cancers that guidelines say should be managed with active surveillance rather than any intervention.
- Method choice has shifted sharply: cryotherapy accounted for nearly 80% of focal therapy procedures in 2010 but only ~20% by 2023, overtaken by laser ablation (~45%) and HIFU (~35%).
- Skeptics like Tyler Seibert at UC San Diego argue head-to-head randomized trials comparing focal therapy to standard treatments are still missing, and note that patients enthusiastic about focal therapy are often reluctant to enroll in such trials.
- Medicare covers focal therapy but many commercial insurers do not — Denver's Chris Brosseau paid $17,000 out of pocket and said, 'I'm super happy with it. I have zero side effects.'
Why it matters: The treatment divide affects the tens of thousands of U.S. men diagnosed with localized prostate cancer each year: focal therapy patients report far fewer side effects than surgery (which causes permanent incontinence in 5–10% and erectile dysfunction in more than half), but most commercial insurers won't cover a procedure that the AUA still calls experimental — leaving patients like Chris Brosseau paying $17,000 out of pocket for an option that guidelines say needs more randomized trial evidence.
Ask SkimNews
